At its meeting on 18th April 2018 the Regional Medicines Optimisation Committee (RMOC) (Midlands and East) reviewed issues pertaining to safety considerations when adopting any insulin preparation onto a local formulary.

The RMOC programme has now issued guidance to formulary committees/ Area Prescribing Committees on this subject.

The guidance is also available as a checklist which is intended to be completed as part of the evidence-gathering process alongside clinical and cost-effectiveness data.